ACTHREL by Ferring Pharmaceuticals is clinical pharmacology pharmacodynamics in normal subjects, intravenous administration of corticorelin results in a rapid and sustained increase of plasma acth levels and a near parallel increase of plasma cortisol. First approved in 1996.
Drug data last refreshed 35m ago · AI intelligence enriched 2d ago
ACTHREL (corticorelin) is a synthetic corticotropin-releasing hormone (CRH) analog administered via intravenous injection. It stimulates rapid and sustained release of plasma ACTH and cortisol, used diagnostically to assess hypothalamic-pituitary-adrenal (HPA) axis function. The drug elicits dose-dependent ACTH and cortisol responses with peak levels reached within 10-15 minutes for ACTH and 30-60 minutes for cortisol.
Product approaching loss of exclusivity with modest competitive pressure (30%); team size likely minimal given diagnostic-only use case and mature lifecycle status.
CLINICAL PHARMACOLOGY Pharmacodynamics In normal subjects, intravenous administration of corticorelin results in a rapid and sustained increase of plasma ACTH levels and a near parallel increase of plasma cortisol. In addition, intravenous administration of corticorelin to normal subjects causes a…
Worked on ACTHREL at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ACTHREL is a niche diagnostic injectable with zero linked job openings, indicating a lean, legacy-focused commercial footprint at Ferring Pharmaceuticals. Career opportunities are limited to specialist roles in medical affairs and regulatory support rather than growth-oriented commercial positions.